Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia

Table 1

Summary of treatment response and related toxicities.

	Case 1				Case 2
Cycle	1	2	3	4	1	2
Treatment	DAC^a; +VEN^b	DAC; +VEN	IVP^c	DAC; +VEN; +VP^d	AZA^e; +VEN	IA^f
Response	CRi^g	Relapse	CR^h	CR	CR	CR
Anemia†	3-4	2–4	2–4	2-3	3-4	2-3
Thrombocytopenia†	1–4	1–4	1–4	1–4	1–4	1–4
Neutropenia†	1–4	1–4	3-4	4	1–4	1–4
Gastrointestinal toxicities†	1-2	1-2	1-2	1-2	1-2	1-2

^aDAC, decitabine; ^bVEN, venetoclax; ^cIVP, idarubicin, vindesine, and dexamethasone; ^dVP, vindesine and dexamethasone; ^eAZA, azacitidine; ^fIA, idarubicin and cytarabine; ^gCRi, complete remission with incomplete blood count recovery; ^hCR, complete remission. †CTCAE V5.0: National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. [2].